Skip to content

Challenges and opportunities for innovation in Endometriosis

Challenges and opportunities for innovation in Endometriosis

Challenges and opportunities for innovation in Endometriosis with Dr. Liliane Brunner Halbach

Challenges and opportunities for innovation in Endometriosis

Join us for the second episode of Scailyte’s Endometriosis Awareness Series, where Cinzia Donato interviews Dr. Liliane Brunner Halbach on the “Challenges and opportunities for innovation in endometriosis”.

Dr. Liliane Halbach is an experienced healthcare expert with 20+ years of global experience in drug research and development, global product strategy, and business development. With a MSc in Pharmacy and a PhD in Pharmacology from the University of Basel, Switzerland, she has worked in different roles in headquarters and affiliates of Novartis, Roche, and AstraZeneca in Switzerland, Spain, the US, and Singapore.

In addition to her work in the pharmaceutical industry, Dr. Liliane Halbach has been involved with SPARK, a mentoring program that helps researchers bring ideas to a proof-of-concept stage, since 2012, and now leads SPARK Zurich. Two years ago, she joined the Artemis group, a team of experts from VC and Pharma with the goal to bring more innovation to women’s health. After two years of talking to stakeholders and analyzing the gaps, the group founded Artemis Women’s Health Foundation in February 2023 to connect the ecosystem of investors with innovators and find solutions to the issues observed in women’s health.

In this episode, Dr. Liliane Halbach shares her insights on the challenges and opportunities for innovation in endometriosis. Don’t miss out on this exciting conversation and join us to learn more about the latest developments in the field of endometriosis research and innovation.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Transforming Healthcare with Unmatched Biomarker Discovery Power

Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...

Read more

Recent News

LSX Congress USA 2023

Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...

Read more

Recent News

Unveiling ScaiVision's Clinical Potential

Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...

Read more

Recent News

ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier

In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...

Read more

Recent News

Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform

Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...

Read more

Recent News

Empowering Precision Healthcare with Unparalleled Discovery Potential

From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...

Read more

Recent News

Accelerating Discoveries with Scailyte's Speed Strength

In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...

Read more

Recent News

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...

Read more

Recent News

01 /04

Transforming Healthcare with Unmatched Biomarker Discovery Power

Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...

Read more

LSX Congress USA 2023

Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...

Read more

Recent News

02 /04

Unveiling ScaiVision's Clinical Potential

Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...

Read more

ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier

In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...

Read more

Recent News

03 /04

Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform

Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...

Read more

Empowering Precision Healthcare with Unparalleled Discovery Potential

From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...

Read more

Recent News

04 /04

Accelerating Discoveries with Scailyte's Speed Strength

In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...

Read more

Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth

At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...

Read more

Recent News